.AstraZeneca\'s Farxiga shows strength in largest ever SGLT2 inhibitor cardiovascular outcomes study httpbit.ly2PRVTYFÂ pharma .pic.twitter.comFAcMFvqD5l
.@AstraZeneca's Farxiga shows strength in largest ever SGLT2 inhibitor cardiovascular outcomes study http://bit.ly/2PRVTYF #pharma .pic.twitter.com/FAcMFvqD5l
More From BioPortfolio on ".@AstraZeneca's Farxiga shows strength in largest ever SGLT2 inhibitor cardiovascular outcomes study http://bit.ly/2PRVTYF #pharma .pic.twitter.com/FAcMFvqD5l"